Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years of age or older
- Doctors expect you to live for at least 3 months
- You are able to carry out basic daily activities, even if you have some limitations (confirm with trial site for exact activity level required)
- You have been confirmed to have Primary Central Nervous System Lymphoma (a type of brain lymphoma) based on medical records or brain scans
- If you have tumours in the brain tissue, scans taken within the last 28 days must show clear signs that the disease has been getting worse, with at least one measurable affected area of a specific size (confirm with trial site)
- If the lymphoma only affects the lining around the brain and spinal cord (rather than the brain tissue itself), a spinal fluid test and/or scan taken within the last 28 days must show abnormal cells
Who may not be able to join:
- Your lymphoma is only in the eyes, without any involvement of the brain or spinal fluid, or you have a different type of lymphoma (such as T-cell lymphoma or lymphoma that started outside the brain)
- Scans show that lymphoma is present elsewhere in your body, not just in the brain
- You have had a different type of cancer in the past (other than certain minor skin cancers or very early-stage cervical or breast cancer), unless you have been cancer-free for 3 or more years
- You currently have another active cancer that requires treatment
- You have previously been treated with a type of drug called a BTK inhibitor (this applies to one part of the trial only — confirm with trial site)
- You have a history of severe muscle breakdown (a condition called rhabdomyolysis, grade 3 or higher) that did not fully resolve
- Your tumour is causing urgent, uncontrolled problems that need immediate treatment
- You received radiation therapy to the brain or spinal cord within the last 28 days
- You have taken an experimental drug within the last 28 days (or within 5 half-lives of that drug, whichever is sooner), received a stem cell transplant from a donor within the last 60 days, or are still experiencing significant complications from a previous stem cell transplant
- You received chemotherapy or other anti-cancer treatment within the last 14 days (or within 5 half-lives, whichever is sooner) — with some possible exceptions depending on which part of the trial you join (confirm with trial site)
- You have previously had a severe allergic reaction to the study drugs (emavusertib or ibrutinib) or any of their ingredients
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 617-503-6500
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Part A: To determine the safety and tolerability of emavusertib as a monotherapy and in combination with ibrutinib: dose-limiting toxicity (DLT); Part A: Maximum tolerated dose (MTD) of emavusertib as a monotherapy and in combination with ibrutinib measured by dose-limiting toxicities (DLTs); Part A: Recommended Phase 2 Dose (RP2D) of emavusertib as a monotherapy and in combination with ibrutinib based on overall tolerability data; Part B: Overall Response Rate (ORR) in participants with R/R PCNSL; Part C: ORR in participants with R/R PCNSL
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.